the largest trial of chitosan to date, with the largest number
of follow-up visits and the most outcome measures.
Importantly, intention-to-treat analyses and several sensitivity
analyses were used, thus limiting the bias that inevitably
results from restricting analysis to data from ‘completers’
only.